Mereo BioPharma Group (NASDAQ:MREO) Given “Neutral” Rating at JPMorgan Chase & Co.

JPMorgan Chase & Co. reaffirmed their neutral rating on shares of Mereo BioPharma Group (NASDAQ:MREO) in a report published on Monday morning, Marketbeat reports.

MREO has been the topic of several other reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Mereo BioPharma Group in a research note on Thursday, January 22nd. Lifesci Capital upgraded shares of Mereo BioPharma Group to a “hold” rating in a research note on Thursday, March 19th. BTIG Research reiterated a “buy” rating and set a $1.00 target price on shares of Mereo BioPharma Group in a research report on Friday, January 16th. Jefferies Financial Group lowered shares of Mereo BioPharma Group from a “buy” rating to a “hold” rating in a research note on Tuesday, December 30th. Finally, Robert W. Baird set a $1.00 price target on shares of Mereo BioPharma Group in a report on Monday, December 29th. Three equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Mereo BioPharma Group presently has a consensus rating of “Hold” and a consensus target price of $3.25.

Mereo BioPharma Group Trading Up 0.2%

MREO stock opened at $0.34 on Monday. The firm has a market cap of $54.52 million, a PE ratio of -5.71 and a beta of 0.34. The stock has a 50-day moving average price of $0.44 and a 200-day moving average price of $1.30. Mereo BioPharma Group has a 1-year low of $0.20 and a 1-year high of $3.05.

Mereo BioPharma Group (NASDAQ:MREO) last announced its earnings results on Thursday, March 19th. The company reported ($0.01) EPS for the quarter, meeting the consensus estimate of ($0.01). On average, analysts forecast that Mereo BioPharma Group will post -0.03 earnings per share for the current year.

Institutional Trading of Mereo BioPharma Group

Several hedge funds have recently bought and sold shares of MREO. Marex Group plc bought a new stake in Mereo BioPharma Group during the 2nd quarter valued at $27,000. State of New Jersey Common Pension Fund D acquired a new stake in shares of Mereo BioPharma Group in the 3rd quarter worth about $32,000. Virtu Financial LLC bought a new position in Mereo BioPharma Group in the 3rd quarter valued at about $33,000. Squarepoint Ops LLC lifted its position in Mereo BioPharma Group by 45.4% in the 3rd quarter. Squarepoint Ops LLC now owns 30,055 shares of the company’s stock valued at $62,000 after acquiring an additional 9,387 shares in the last quarter. Finally, Forefront Analytics LLC boosted its stake in Mereo BioPharma Group by 73.4% during the 3rd quarter. Forefront Analytics LLC now owns 33,180 shares of the company’s stock valued at $68,000 after purchasing an additional 14,042 shares during the last quarter. Institutional investors and hedge funds own 62.83% of the company’s stock.

Mereo BioPharma Group News Roundup

Here are the key news stories impacting Mereo BioPharma Group this week:

• Neutral Sentiment: JPMorgan reaffirmed a “neutral” rating on MREO, indicating no change to analyst guidance or a fresh catalyst from the sell‑side. Benzinga Coverage
• Negative Sentiment: Faruqi & Faruqi filed a notice reminding investors of the April 6, 2026 deadline to seek lead‑plaintiff status in the securities class action alleging misstatements during the June 5, 2023–Dec 26, 2025 class period — a development that typically raises litigation risk and can pressure the share price. Faruqi & Faruqi Notice
• Negative Sentiment: Rosen Law Firm issued lead‑plaintiff solicitation notices covering the same class period and deadline, increasing public awareness and the chance of active litigation or claim aggregation. Rosen Law Firm Notice
• Negative Sentiment: The Schall Law Firm published a similar solicitation/notice about the securities fraud suit and the April 6 deadline, reinforcing media attention and potential legal action against Mereo. Schall Law Firm Notice
• Negative Sentiment: The DJS Law Group also announced the securities suit and solicited potential lead plaintiffs, adding to the chorus of firms publicizing the litigation and increasing the likelihood of active claim proceedings. DJS Law Group Notice

Mereo BioPharma Group Company Profile

Mereo BioPharma Group plc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for rare diseases, oncology and severe respiratory conditions. The company pursues an asset‐centric model, in which it in-licenses or acquires clinical-stage small molecules and monoclonal antibodies with established safety profiles. By concentrating resources on a select number of programs, Mereo aims to accelerate proof-of-concept studies and maximize the potential value of each therapeutic candidate.

Mereo’s pipeline includes investigational therapies for skeletal disorders, such as setrusumab (BPS-804) for osteogenesis imperfecta, and treatments for acute and chronic respiratory diseases.